BioCentury
ARTICLE | Clinical News

GPI-5693: Began Phase I trial

December 18, 2000 8:00 AM UTC

Guilford Pharmaceuticals Inc. (GLFD), Baltimore, Md. Product: GPI-5693 Business: Neurological Therapeutic category: Neuroprotectant Target: NAALADase Description: Inhibitor of N-acetylated alpha-link...